Graybug Vision (NASDAQ:GRAY) PT Lowered to $2.50 at Cantor Fitzgerald

Graybug Vision (NASDAQ:GRAYGet Rating) had its price target trimmed by Cantor Fitzgerald from $4.00 to $2.50 in a report released on Wednesday, The Fly reports. Cantor Fitzgerald also issued estimates for Graybug Vision’s FY2022 earnings at ($1.97) EPS.

A number of other analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Graybug Vision from a sell rating to a hold rating in a research report on Wednesday, April 27th. Wedbush reissued a neutral rating and set a $3.00 target price on shares of Graybug Vision in a research report on Thursday, March 31st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Graybug Vision presently has an average rating of Hold and an average price target of $3.56.

Graybug Vision stock opened at $0.83 on Wednesday. The business has a 50 day moving average of $1.14 and a 200-day moving average of $1.70. Graybug Vision has a 1 year low of $0.72 and a 1 year high of $7.06.

Graybug Vision (NASDAQ:GRAYGet Rating) last released its earnings results on Thursday, March 10th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). On average, sell-side analysts predict that Graybug Vision will post -1.71 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in shares of Graybug Vision by 221.3% in the 1st quarter. Renaissance Technologies LLC now owns 35,341 shares of the company’s stock worth $43,000 after purchasing an additional 24,341 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Graybug Vision by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 455,572 shares of the company’s stock worth $561,000 after purchasing an additional 23,846 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Graybug Vision in the 1st quarter worth $125,000. Advisor Group Holdings Inc. bought a new position in shares of Graybug Vision in the 1st quarter worth $740,000. Finally, State Street Corp lifted its holdings in shares of Graybug Vision by 70.7% in the 4th quarter. State Street Corp now owns 35,073 shares of the company’s stock worth $64,000 after purchasing an additional 14,525 shares in the last quarter. Institutional investors own 52.88% of the company’s stock.

About Graybug Vision (Get Rating)

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Featured Articles

The Fly logo

Analyst Recommendations for Graybug Vision (NASDAQ:GRAY)

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.